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Background:  Relation of antiplatelet therapy (APT) discontinuation with the risk of adverse cardiovascular events has not been adequately 
addressed yet.
methods:  In the CREDO-Kyoto Registry Cohort-2 enrolling 15939 consecutive patients undergoing first coronary revascularization between 2005 
and 2007, 10470 patients underwent either percutaneous coronary intervention with bare-metal stents (BMS) only (N=5392) or sirolimus-eluting 
stents (SES) only (N=5078). During 7-year follow-up, daily APT status in terms of thienopyridines- and aspirin-use was recorded. Proportions of 
patients taking dual APT in the SES and BMS groups were 67.3% and 33.4% at 1-year, and 48.7% and 24.3% at 5-year, respectively. We connected 
adverse events to the APT status on the previous day of the events. Each incidence density rate of events was calculated by dividing the number of 
events by the patient-day in the interest study period.
results:  Beyond 6-month after coronary stenting, no-APT (discontinuation of both aspirin and thienopyridine) as compared with single-APT/dual-
APT was associated with higher incidence of ST in the SES group (integrated incidence rates: 1.02 versus 0.3/0.15, P=0.012/P<0.001), but not in 
the BMS group (0.31 versus 0.08/0.11, P=NS). No-APT was also associated with higher incidence of both spontaneous myocardial infarction (MI) 
and stroke in both SES (1.28 versus 0.19/0.36, P<0.001/P=0.002, and 2.9 versus 0.85/1.3, P<0.001/P<0.001) and BMS groups (0.92 versus 
0.46/0.35, P=NS/P=0.038, and 1.76 versus 0.85/1.3, P<0.022/P<0.014).
conclusions:  Discontinuation of both aspirin and thienopyridines was associated with higher risk for serious adverse cardiovascular events, while 
single APT as compared with dual-APT was not associated with increased risk for these events.
